Oncolytic virus delivery
Its proprietary RedTail platform is designed for systemic delivery of modified oncolytic viruses with genetic payloads activated at the tumor site.
Source: LinkedIn company description · Retrieved October 13, 2026
Calidi Biotherapeutics is developing a new modality in cancer treatment.
The company is advancing therapies for solid tumors. Calidi is progressing toward early clinical data.
Based on the company’s public LinkedIn information, supplied through RevenueBase.
Its proprietary RedTail platform is designed for systemic delivery of modified oncolytic viruses with genetic payloads activated at the tumor site.
Source: LinkedIn company description · Retrieved October 13, 2026
Supported appearances on published RevenueBase lists, including available memberships beyond displayed rankings.
Positions describe ordering within each source list. See how lists are built ↗
Embeddable award for your website
RevenueBase prepared this profile from the company’s public LinkedIn information and RevenueBase company data. These source records were retrieved on October 13, 2026. AI helped summarize these sources, with a separate automated check against the source text completed on November 4, 2026. Directory positions use company-contact counts from separate saved list snapshots dated September 11, 2026, September 15, 2026, September 16, 2026, September 18, 2026, September 19, 2026, September 21, 2026 and October 8, 2026. How the company lists are built.
Share a correction, your relationship to the company, and supporting sources. Requests are reviewed before changes are published.
Explore more companies by name, headquarters and business focus.